BR9810007A - Compostos, composição farmacêutica, uso deum composto, e, processos para o tratamento de um paciente humano ou animal que sofre de, ou sujeito a, condições que podem ser melhoradas pela administração de um inibidor do tnf-alfa e para a preparação de um composto - Google Patents

Compostos, composição farmacêutica, uso deum composto, e, processos para o tratamento de um paciente humano ou animal que sofre de, ou sujeito a, condições que podem ser melhoradas pela administração de um inibidor do tnf-alfa e para a preparação de um composto

Info

Publication number
BR9810007A
BR9810007A BR9810007-6A BR9810007A BR9810007A BR 9810007 A BR9810007 A BR 9810007A BR 9810007 A BR9810007 A BR 9810007A BR 9810007 A BR9810007 A BR 9810007A
Authority
BR
Brazil
Prior art keywords
compound
compounds
hydrogen
optionally substituted
heteroaryl
Prior art date
Application number
BR9810007-6A
Other languages
English (en)
Other versions
BR9810007B1 (pt
Inventor
Paul Lindsay Bamborough
Alan John Collis
Frank Halley
Richard Alan Lewis
David John Lythgoe
Jeffrey Mark Mckenna
Iain Mcfarlane Mclay
Barry Porter
Andrew James Ratcliffe
Paul Andrew Wallace
Original Assignee
Rhone Poulenc Rorer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712270.9A external-priority patent/GB9712270D0/en
Priority claimed from GBGB9724678.9A external-priority patent/GB9724678D0/en
Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd
Publication of BR9810007A publication Critical patent/BR9810007A/pt
Publication of BR9810007B1 publication Critical patent/BR9810007B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"COMPOSTOS, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSOS PARA O TRATAMENTO DE UM PACIENTE HUMANO OU ANIMAL QUE SOFRE DE, OU SUJEITO A, CONDIçõES QUE PODEM SER MELHORADAS PELA ADMINISTRAçãO DE UM INIBIDOR DO TNF-ALFA E PARA A PREPARAçãO DE UM COMPOSTO" Compostos da fórmula (I) são descritos, em que R^ 1^ é heteroarila opcionalmente substituída; R^ 2^ é arila opcionalmente substituída ou heteroarila opcionalmente substituída; R^ 3^ é um grupo -L^ 1^-R^ 7^ ou -L^ 2^-R^ 8^ [onde L^ 1^ é uma ligação alquileno opcionalmente substituída; R^ 7^ é hidrogênio, arila, ciano, cicloalquila, heteroarila, heterocicloalquila, nitro, -S(O)~ n~R^ 9^, -NHSO~ 2~R^ 9^, -C(=Z)OR^ 10^, -C(=Z)R^ 10^, -N(R^ 11^)-C(=Z)R^ 9^, -NY^ 1^Y^ 2^, -SO^ 2^-NY^ 1^Y^ 2^, -C(=Z)-NY^ 1^Y^ 2^, -N(R^ 11^)-C(=Z)-NY^ 1^Y^ 2^, -N(OR^ 10^)-C(=Z)-NY^ 1^Y^ 2^, -N(OR^ 10^)-C(=Z)R^ 10^, -C(=NOR^ 10^)R^ 10^, -C(=Z)NR^ 10^OR^ 12^, -N(R^ 11)-C(=NR^ 13^)-NY^ 1^Y^ 2^ ou -N(R^ 11^)-C(=Z)OR^ 11^; L^ 2^ é uma ligação direta ou uma cadeia carbónica reta ou ramificada que compreenda de 2 a cerca de 6 átomos de carbono e contenha uma ligação carbono-carbono dupla ou tripla; e R^ 8^ é hidrogênio, arila, cicloalquenila, cicloalquila, heteroarila ou heterocicloalquila]; R^ 4^ é um grupo -L^ 3^-R^ 14^ [onde L^ 3^ é uma ligação direta ou uma ligação alquileno opcionalmente substituída e R^ 14^ é hidrogênio, alquila, azido, hidróxi, alcóxi, arila, arilalquilóxi, arilóxi, carboxi (ou um bioisóstero ácido), cicloalquilóxi, heteroarila, heteroarilalquilóxi, heteroarilóxi, heterocicloalquila, heterocicloalquilóxi, nitro, -NY^ 4^Y^ 5^, -N(R^ 10^)-C(=Z)R^ 15^, -NH-C(=Z)-NH-R^ 15^, -NH-C(=Z)-NH-L^ 4^-R^ 16^, -N(R^ 10^)-SO~ 2~-R^ 15^, -N(R^ 10^)-SO~ 2~-L^ 4^-R^ 16^, -S(O)~ n~R^ 9^, -C(=Z)-NY^ 4^Y^ 5^ ou -C(=Z)-OR^ 9^; R^ 5^ é hidrogênio, alquila ou hidroxialquila; ou R^ 4^ e R^ 5^, quando ligados ao mesmo átimo de carbono, podem formar com o dito átomo de carbono um anel cicloalquílico, cicloalquenílico ou heteocicloalquílico ou um grupo C=CH~ 2~; R^ 6^ é hidrogênio ou alquila; e m é zero ou um número inteiro 1 ou 2; e N-óxidos destes e seus pró-medicamentos; e sais e solvatos (por exemplo, hidratos) farmaceuticamente aceitáveis dos compostos da fórmula (I) e N-óxidos destes e seus pró-medicamentos. Os compostos são inibidores de TNF e são utilizáveis como produtos farmacêuticos.
BRPI9810007-6A 1997-06-12 1998-06-12 compostos, e, derivados da resina de merrifield. BR9810007B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9712270.9 1997-06-12
GBGB9712270.9A GB9712270D0 (en) 1997-06-12 1997-06-12 Chemical compounds
US5218597P 1997-07-10 1997-07-10
US60/052185 1997-07-10
GB9724678.9 1997-11-21
GBGB9724678.9A GB9724678D0 (en) 1997-11-21 1997-11-21 Chemical compounds
US8549998P 1998-05-14 1998-05-14
US60/085499 1998-05-14
PCT/GB1998/001711 WO1998056788A1 (en) 1997-06-12 1998-06-12 Imidazolyl-cyclic acetals

Publications (2)

Publication Number Publication Date
BR9810007A true BR9810007A (pt) 2000-08-15
BR9810007B1 BR9810007B1 (pt) 2010-04-06

Family

ID=27451664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9810007-6A BR9810007B1 (pt) 1997-06-12 1998-06-12 compostos, e, derivados da resina de merrifield.

Country Status (26)

Country Link
US (2) US6602877B1 (pt)
EP (1) EP0988301B1 (pt)
JP (1) JP4380803B2 (pt)
KR (1) KR100704059B1 (pt)
CN (1) CN100443481C (pt)
AT (1) ATE335735T1 (pt)
AU (1) AU742293B2 (pt)
BR (1) BR9810007B1 (pt)
CA (1) CA2293436C (pt)
CY (1) CY1105238T1 (pt)
CZ (1) CZ9904452A3 (pt)
DE (1) DE69835518T2 (pt)
DK (1) DK0988301T3 (pt)
ES (1) ES2270520T3 (pt)
HK (1) HK1032586A1 (pt)
HU (1) HUP0003309A3 (pt)
IL (2) IL133311A0 (pt)
NO (1) NO326660B1 (pt)
NZ (1) NZ501714A (pt)
PL (1) PL199893B1 (pt)
PT (1) PT988301E (pt)
RU (1) RU2221795C2 (pt)
SK (2) SK286940B6 (pt)
TR (1) TR199903098T2 (pt)
TW (1) TWI235751B (pt)
WO (1) WO1998056788A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
ATE266399T1 (de) * 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
DE69903976T2 (de) 1998-12-16 2003-07-24 Aventis Pharma Ltd Heteroaryl-zyklische acetale
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US6291457B1 (en) * 1999-07-01 2001-09-18 Merck & Co., Inc. Compounds having cytokine inhibitory activity
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN1543346A (zh) * 1999-11-22 2004-11-03 ʷ��˿�������ȳ�ķ���޹�˾ 新化合物
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
EP1235814B1 (en) 1999-11-23 2004-11-03 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical INHIBITOR OF JNK
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
WO2003022837A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TWI317286B (en) 2003-12-31 2009-11-21 Targeting delivery system
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1934213A1 (en) 2005-09-30 2008-06-25 Astra Zeneca AB Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
CN101296917A (zh) * 2005-10-24 2008-10-29 霍夫曼-拉罗奇有限公司 由法沃斯基重排制备环状缩酮化酮及该方法在制备葡糖激酶活化剂70中的应用
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
CA2760911A1 (en) * 2009-05-19 2010-11-25 George E. Davis Compounds and methods for controlling fungi
CN111356687B (zh) * 2019-03-27 2021-03-30 广州必贝特医药技术有限公司 含嘧啶的三取代咪唑类化合物及其应用
MX2022011143A (es) 2020-03-11 2022-10-13 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4175127A (en) 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
GB2123831B (en) 1981-07-20 1986-01-15 Ciba Geigy Ag Trisubstituted oxazo compounds
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4728656A (en) 1985-12-12 1988-03-01 Smithkline Beckman Corporation 2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
ATE60776T1 (de) 1986-11-21 1991-02-15 Ciba Geigy Ag Ungesaettigte phosphonsaeure und derivate.
US4837350A (en) 1986-12-15 1989-06-06 Ciba-Geigy Corporation Process for the preparation of benzoin sulfonates
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
AU6307690A (en) * 1989-09-27 1991-04-11 Rhone-Poulenc Sante Imidazoles
GB9020889D0 (en) * 1990-09-25 1990-11-07 May & Baker Ltd New compositions of matter
US5102848A (en) 1990-09-28 1992-04-07 Union Carbide Chemicals & Plastics Technology Corporation Catalyst composition for oxidation of ethylene to ethylene oxide
GB9106508D0 (en) * 1991-03-27 1991-05-15 Rhone Poulenc Rorer Ltd New compositions of matter
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
WO1993014082A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
EP1306377A3 (en) 1993-11-08 2003-05-07 Smithkline Beecham Corporation Pyridyl-oxazoles and their use as cytokines inhibitors
EP0653421B1 (en) 1993-11-12 1997-01-15 Ishihara Sangyo Kaisha Ltd. Process for preparing 2-cyanoimidazole compounds
WO1996016040A1 (en) 1994-11-23 1996-05-30 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
DE69627006T2 (de) 1995-08-10 2004-01-15 Merck & Co Inc 2-substituierte aryl-pyrrolen, zusammensetzungen solche verbindungen enthaltend und deren verwendung
EP0871444A4 (en) 1995-08-10 1999-01-13 Merck & Co Inc 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
AU702146B2 (en) 1995-10-06 1999-02-11 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
AU7529096A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP3912758B2 (ja) 1996-02-16 2007-05-09 富士フイルム株式会社 １，１−ジ置換−１Ｈ−ベンゾ〔ｅ〕インドール化合物の製造方法及び４〜９位ヒドロキシ基置換の該化合物
JP2000507545A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
GB0515625D0 (en) 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle

Also Published As

Publication number Publication date
PL337314A1 (en) 2000-08-14
HUP0003309A3 (en) 2002-02-28
ES2270520T3 (es) 2007-04-01
NZ501714A (en) 2001-09-28
DE69835518D1 (de) 2006-09-21
SK286940B6 (sk) 2009-07-06
TWI235751B (en) 2005-07-11
AU742293B2 (en) 2001-12-20
EP0988301B1 (en) 2006-08-09
AU7925998A (en) 1998-12-30
KR100704059B1 (ko) 2007-04-05
NO996120L (no) 2000-01-24
CN100443481C (zh) 2008-12-17
JP2002503245A (ja) 2002-01-29
DK0988301T3 (da) 2006-11-13
CA2293436A1 (en) 1998-12-17
US6989395B2 (en) 2006-01-24
PL199893B1 (pl) 2008-11-28
CN1273584A (zh) 2000-11-15
IL133311A0 (en) 2001-04-30
ATE335735T1 (de) 2006-09-15
WO1998056788A1 (en) 1998-12-17
RU2221795C2 (ru) 2004-01-20
KR20010013683A (ko) 2001-02-26
TR199903098T2 (xx) 2000-07-21
CA2293436C (en) 2010-10-26
IL133311A (en) 2008-11-26
CY1105238T1 (el) 2010-03-03
SK171099A3 (en) 2001-12-03
EP0988301A1 (en) 2000-03-29
JP4380803B2 (ja) 2009-12-09
BR9810007B1 (pt) 2010-04-06
CZ9904452A3 (cs) 2002-02-13
PT988301E (pt) 2006-10-31
US20040038991A1 (en) 2004-02-26
HK1032586A1 (en) 2001-07-27
HUP0003309A2 (hu) 2002-01-28
NO996120D0 (no) 1999-12-10
US6602877B1 (en) 2003-08-05
DE69835518T2 (de) 2007-08-09
NO326660B1 (no) 2009-01-26

Similar Documents

Publication Publication Date Title
BR9810007A (pt) Compostos, composição farmacêutica, uso deum composto, e, processos para o tratamento de um paciente humano ou animal que sofre de, ou sujeito a, condições que podem ser melhoradas pela administração de um inibidor do tnf-alfa e para a preparação de um composto
BR0014137A (pt) Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica
CA2355075A1 (en) Heteroaryl-cyclic acetals
WO1998056788B1 (en) Imidazolyl-cyclic acetals
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BR0017038A (pt) Azaindóis
BR9814340A (pt) Derivados de indol como inibidores de fator xa
HUP0301167A2 (hu) Neurológiai rendellenességek kezelésére felhasználható szulfonil-pirrolidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CO5080743A1 (es) Benzocicloheptenos, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen. .
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
BR9912612A (pt) Composto de maleimida dissubstituìdo e seu usofarmacêutico
BR9908706A (pt) Derivado de benzofuril-alfa-pirona, composição farmacêutica, acentuador de metabolismo de lipìdeos, inibidor de biossìntese de triglicerìdeos, agente redutor de triglicerìdeos do sangue, agente elevador de hdl do sangue, agente profilático para a arteriosclerose, e, agente de tratamento para a arteriosclerose
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
TR199900401T2 (xx) Bidentat metaloproteaz inhibit�rleri.
DK163144C (da) Diethylaminoalkoxybenzhydrolderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat og fremgangsmaade til fremstilling heraf
HUP9700810A2 (hu) Diozmetinsavak és -észterek, és a vegyületeket tartalmazó gyógyszerkészítmények
TW367324B (en) Prostaglandin derivatives
BR0115454A (pt) Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
HUP0301301A2 (hu) Benzoxazepinon-származékok és szkvalén szintáz inhibitorként való alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DK0966462T3 (da) Heterocykliske forbindelser, der er egnede som oxidosqualencyklaseinhibitorer
RU95101437A (ru) Содержащее производные 3-фенилсульфонил-3,7-диазабицикло [3,3,1] нонана лекарственное средство, способ получения производных 3-фенилсульфонил-3,7-диазабицикло-[3,3,1]-нонана
US5763479A (en) Naphthoquinone derivatives for the treatment of chronic inflammation
DK1990343T3 (da) Azaindoler

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07D 401/04, C07D 403/04, C07D 405/14, C07D 409/14,C07D 413/14, C07D 491/10,C07D 493/10, A61K 31/4439/, A61K 31/444, A61K 31/496, A61K 31/506, A61K 31/5377, A61P 3/00, A61P 11/06, A61P 19/02

Ipc: C07D 401/04 (2007.01), C07D 403/04 (2007.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: AVENTIS PHARMA LIMITED (GB)

Free format text: TRANSFERIDO DE: RHONE-POULENC RORER LIMITED

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 15A, 16A E 17A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.